Cat. No.: HY-B1193

Terfenadine

(Synonyms: (±)-Terfenadine; MDL-991)

4 Cited Publications

Avis client

Based on 4 publication(s) in Google Scholar

Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC₅₀ of 204 nM. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca²⁺ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 50679-08-8
Formule: C₃₂H₄₁NO₂
Masse moléculaire:471.67

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Terfenadine Chemical Structure

CAS No.: 50679-08-8

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC₅₀ of 204 nM^[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca²⁺ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9^[2].

IC₅₀ & Target

H₁ Receptor

Caspase-4

Caspase-2

Caspase-9

Voir tous les produits spécifiques à Isoform Histamine Receptor :

Voir tous les produits spécifiques à Isoform Caspase :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	56 nM Compound: Terfenadine	Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1 Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1	[PMID: 12729675]
CHO	IC₅₀	0.93 μM Compound: terfenadine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	56 μM Compound: 41, Terfenadine	Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay	[PMID: 16931010]
HEK293	IC₅₀	0.03 μM Compound: Terfenadine	Inhibition of human ERG S624A mutant expressed in HEK293 cells by whole cell patch clamp method Inhibition of human ERG S624A mutant expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	0.03 μM Compound: Terfenadine	Inhibition of human ERG td[wt:F656A] mutant expressed in HEK293 cells by whole cell patch clamp method Inhibition of human ERG td[wt:F656A] mutant expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	0.03 μM Compound: Terfenadine	Inhibition of human ERG td[wt:Y652A] mutant expressed in HEK293 cells by whole cell patch clamp method Inhibition of human ERG td[wt:Y652A] mutant expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	0.03 μM Compound: Terfenadine	Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method Inhibition of wild-type human ERG expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	0.35 μM Compound: Terfenadine	Inhibition of human ERG Y652A mutant expressed in HEK293 cells by whole cell patch clamp method Inhibition of human ERG Y652A mutant expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	0.96 μM Compound: Terfenadine	Inhibition of human ERG F656A mutant expressed in HEK293 cells by whole cell patch clamp method Inhibition of human ERG F656A mutant expressed in HEK293 cells by whole cell patch clamp method	[PMID: 19260734]
HEK293	IC₅₀	971 nM Compound: Terfenadine	Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA	[PMID: 21300721]
HEK293	IC₅₀	0.056 μM Compound: figure 2, R2C1	Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis Inhibition of human Erg expressed in HEK293 cells assessed as rubidium efflux after 4 hrs by atomic absorbance spectrometric analysis	[PMID: 22542010]
HEK293	IC₅₀	1.32 μM Compound: Terfenadine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	130 nM Compound: 1a, terfenadine	Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method Displacement of [3H]astemizole from human ERG expressed in HEK293 cells by scintillation counting method	[PMID: 25238555]
HEK293	IC₅₀	0.022 μM Compound: Terfenadine	Inhibition of human ERG expressed in HEK293 cells by patch clamp method Inhibition of human ERG expressed in HEK293 cells by patch clamp method	[PMID: 28481112]
HEK293	IC₅₀	0.086 μM Compound: Terfenadine	Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual patch clamp assay Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by manual patch clamp assay	[PMID: 30624934]
HEK293	IC₅₀	1.2 μM Compound: Terfenadine	Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay Inhibition of human ERG expressed in HEK293 cells measured after 30 mins by FluxOR dye based FLIPR TETRA assay	[PMID: 32392053]
L929	IC₅₀	312 nM Compound: rac-1	Inhibition of human ERG in L929 cells at 10 uM by whole cell patch-clamp assay Inhibition of human ERG in L929 cells at 10 uM by whole cell patch-clamp assay	[PMID: 19660947]
L929	IC₅₀	312 nM Compound: rac-1	Inhibition of human ERG in L929 cells by whole cell patch-clamp assay Inhibition of human ERG in L929 cells by whole cell patch-clamp assay	[PMID: 19660947]
LLC-PK1	IC₅₀	1.4 μM Compound: Terfenadine	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	1.4 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	2 μM Compound: Terfenadine	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	2 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	[PMID: 12699389]
LLC-PK1	IC₅₀	23 μM Compound: Terfenadine	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	23 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	[PMID: 12699389]
NIH-3T3-G185	IC₅₀	1.8 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	2.5 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	2.7 μM Compound: Terfenadine	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
Sf9	IC₅₀	8.1 μM Compound: terfenadine	Inhibition of human recombinant CYP2J2 expressed in baculovirus-infected Sf9 insect cells Inhibition of human recombinant CYP2J2 expressed in baculovirus-infected Sf9 insect cells	[PMID: 16495056]
Ventricular myocyte	IC₅₀	375 nM Compound: Terfenadine	Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes	[PMID: 21300721]
Ventricular myocyte	IC₅₀	0.142 μM Compound: Terfenadine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Terfenadine ((±)-Terfenadine) (4-20 μM; 24 hours) induces dose and time-dependent apoptosis on A375 melanoma cells. The IC₅₀ after 24 h of TEF treatment in complete medium was 10.4 μM for A375 cells, 9.9 μM for Hs294T cells and 9.6 for HT144 cells^[2].
Terfenadine (2-10 μM; 8 hours) induces dose-dependent cytotoxicity^[2].
Terfenadine (10 μM; 8 hours) causes a massive vacuolization of the cytoplasm and autophagic vacuoles of both double and multiple membranes and at various stages. Terfenadine induces autophagy by ROS-dependent and -independent mechanisms^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

A375, HT144 and Hs294T cells
Concentration:

4, 8, 12, 16, 20 μM
Incubation Time:

24 hours
Result:

Induced dose and time-dependent apoptosis.

Cell Cytotoxicity Assay^[2]

Cell Line:

A375 melanoma cells
Concentration:

2, 4, 6, 8, 10 μM
Incubation Time:

8 hours
Result:

Induces dose-dependent cytotoxicity.

Cell Autophagy Assay^[2]

Cell Line:

A375 cells
Concentration:

10 μM
Incubation Time:

8 hours
Result:

Caused a massive vacuolization of the cytoplasm and autophagic vacuoles of both double and multiple membranes and at various stages.

In Vivo

Terfenadine (p.o.; 40 mg/kg; for 16 days) produces a significant inhibition of tumour growth rate and enhances the anti-cancer effect of EPI in chemo-resistant NSCLC xenograft models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-week-old male BALB/cA-nu mice^[3]
Dosage:

40 mg/kg
Administration:

P.o.; for 16 days
Result:

Produced a significant inhibition of tumour growth rate.

Chemical Information

CAS No. 50679-08-8
Appearance Solid
Masse moléculaire 471.67
Formule C₃₂H₄₁NO₂
Color White to off-white
SMILES

OC(C1=CC=C(C(C)(C)C)C=C1)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2
Synonyms

(±)-Terfenadine; MDL-991
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

ACS Nano

Single-Molecule-Based, Label-Free Monitoring of Molecular Glue Efficacies for Promoting Protein-Protein Interactions Using YaxAB Nanopores. [Abstract]

2024 Nov 12;18(45):31451-31465. PMID: 39482865
Front Immunol

Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model. [Abstract]

2023 Nov 23;14:1282710. PMID: 38077396
Mol Oncol

YAP1::TFE3 mediates endothelial-to-mesenchymal plasticity in epithelioid hemangioendothelioma. [Abstract]

2025 Aug 17. PMID: 40819258
Purdue University

2025 Jul 23.

Solvant et solubilité

In Vitro:

DMSO : ≥ 50 mg/mL (106.01 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1201 mL

10.6006 mL

21.2013 mL

5 mM

0.4240 mL

2.1201 mL

4.2403 mL

10 mM

0.2120 mL

1.0601 mL

2.1201 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (398 KB)
- English - EN (398 KB)
- Français - FR (398 KB)
- Deutsch - DE (398 KB)
- Norwegian - NO (398 KB)
- Español - ES (398 KB)
- Swedish - SV (398 KB)
- Italian - IT (398 KB)
- Portuguese - PT (398 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kamiya K, et al. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci. 2008 Nov;108(3):301-307. [Content Brief]

[2]. Nicolau-Galmés F, et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis. 2011 Dec;16(12):1253-67. [Content Brief]

[3]. An L, et al. Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. Pharmacol Res. 2017 Oct;124:105-115. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1201 mL	10.6006 mL	21.2013 mL	53.0032 mL
	5 mM	0.4240 mL	2.1201 mL	4.2403 mL	10.6006 mL
	10 mM	0.2120 mL	1.0601 mL	2.1201 mL	5.3003 mL
	15 mM	0.1413 mL	0.7067 mL	1.4134 mL	3.5335 mL
	20 mM	0.1060 mL	0.5300 mL	1.0601 mL	2.6502 mL
	25 mM	0.0848 mL	0.4240 mL	0.8481 mL	2.1201 mL
	30 mM	0.0707 mL	0.3534 mL	0.7067 mL	1.7668 mL
	40 mM	0.0530 mL	0.2650 mL	0.5300 mL	1.3251 mL
	50 mM	0.0424 mL	0.2120 mL	0.4240 mL	1.0601 mL
	60 mM	0.0353 mL	0.1767 mL	0.3534 mL	0.8834 mL
	80 mM	0.0265 mL	0.1325 mL	0.2650 mL	0.6625 mL
	100 mM	0.0212 mL	0.1060 mL	0.2120 mL	0.5300 mL

Keywords

Terfenadine

4 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Terfenadine

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Endocrinology Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Lung Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

EMA-Approved Drug Library

Potassium Channel Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Ion Channel Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Terfenadine

Voir tous les produits spécifiques à Isoform Histamine Receptor

Voir tous les produits spécifiques à Isoform Caspase

Activité biologique

Chemical Information

Publications (4)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Terfenadine Related Classifications

Cat. No.: HY-B1193